Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Keros Therapeutics Inc's Business Segments
Keros Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 3
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable13.6%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 0 | 13.6% |
Revenue by Product & Service Category - Q1 FY2026
- Service, Other13.6%
- Service1.2%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service, Other | $ 0 | 13.6% |
| Service | $ 0 | 1.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue by Product & Service Category -
- Service14.3%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service | $ 39 | 14.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Keros Therapeutics Inc's Business Segments
Keros Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for rare genetic diseases characterized by a deficiency in specific proteins. Keros Therapeutics was founded in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics is primarily focused on developing small molecule therapeutics that can modulate the activity of protein targets known to play a critical role in human disease. The company's lead drug candidate, KER-050, is a potent and selective agonist of the erythropoietin receptor (EPOR). The EPOR is a crucial protein involved in the regulation of red blood cell production and survival. KER-050 is currently being evaluated in a Phase 2 clinical trial for treatment for patients with myelodysplastic syndromes (MDS) or myelofibrosis (MF) who are anemic and require red blood cell transfusions.
Keros Therapeutics' pipeline also includes several other drug candidates targeting various disease indications. These include KER-047, a small molecule inhibitor of secretion and TGF-β activation, which is being developed for treatment of fibrotic diseases; KER-012, a small molecule Modulator of the Transforming Growth Factor Beta (TGF-β) Pathway, which is being developed for the treatment of certain fibrotic disorders and cancer; and KER-044, a small molecule activator of a protein that can enhance glucose uptake which is being developed for treatment of certain metabolic disorders, including Type 2 diabetes.
Keros Therapeutics is committed to leveraging its expertise in drug discovery and development to bring novel therapies to patients with unmet medical needs. To this end, the company employs cutting-edge technologies in protein engineering, structural biology, and computer-aided drug design to identify and optimize potential drug candidates. Keros has also established partnerships with academic and industry collaborators to expand its drug discovery capabilities and further augment its pipeline.
The company has a strong management team that includes experienced leaders from the biotech and pharmaceutical industries. Keros Therapeutics' CEO, Jasbir Seehra, has over 25 years of experience in biotech drug discovery and has previously served in leadership roles at Genentech, Inc. and Amgen Inc. The company's scientific co-founders, Drs. Avrum Spira and Benjamin Ebert, are both leading experts in their respective fields of genomics and hematology and have made significant contributions to academic research in these areas.
Overall, Keros Therapeutics is a promising biopharmaceutical company that is focused on developing novel drugs to treat rare genetic diseases where there are limited treatment options. With an experienced management team, promising pipeline, and strong partnerships, Keros Therapeutics is poised to make significant contributions to the advancement of precision medicine.
Keros Therapeutics is primarily focused on developing small molecule therapeutics that can modulate the activity of protein targets known to play a critical role in human disease. The company's lead drug candidate, KER-050, is a potent and selective agonist of the erythropoietin receptor (EPOR). The EPOR is a crucial protein involved in the regulation of red blood cell production and survival. KER-050 is currently being evaluated in a Phase 2 clinical trial for treatment for patients with myelodysplastic syndromes (MDS) or myelofibrosis (MF) who are anemic and require red blood cell transfusions.
Keros Therapeutics' pipeline also includes several other drug candidates targeting various disease indications. These include KER-047, a small molecule inhibitor of secretion and TGF-β activation, which is being developed for treatment of fibrotic diseases; KER-012, a small molecule Modulator of the Transforming Growth Factor Beta (TGF-β) Pathway, which is being developed for the treatment of certain fibrotic disorders and cancer; and KER-044, a small molecule activator of a protein that can enhance glucose uptake which is being developed for treatment of certain metabolic disorders, including Type 2 diabetes.
Keros Therapeutics is committed to leveraging its expertise in drug discovery and development to bring novel therapies to patients with unmet medical needs. To this end, the company employs cutting-edge technologies in protein engineering, structural biology, and computer-aided drug design to identify and optimize potential drug candidates. Keros has also established partnerships with academic and industry collaborators to expand its drug discovery capabilities and further augment its pipeline.
The company has a strong management team that includes experienced leaders from the biotech and pharmaceutical industries. Keros Therapeutics' CEO, Jasbir Seehra, has over 25 years of experience in biotech drug discovery and has previously served in leadership roles at Genentech, Inc. and Amgen Inc. The company's scientific co-founders, Drs. Avrum Spira and Benjamin Ebert, are both leading experts in their respective fields of genomics and hematology and have made significant contributions to academic research in these areas.
Overall, Keros Therapeutics is a promising biopharmaceutical company that is focused on developing novel drugs to treat rare genetic diseases where there are limited treatment options. With an experienced management team, promising pipeline, and strong partnerships, Keros Therapeutics is poised to make significant contributions to the advancement of precision medicine.
Keros Therapeutics Inc. is a prominent biopharmaceutical company that operates at the forefront of drug discovery and development, focusing on cutting-edge therapeutics that target critical protein-protein interactions (PPIs). The company is dedicated to addressing significant unmet medical needs across multiple disease areas, with a particular emphasis on oncology and rare diseases. Below is an extensive overview of the company’s segments, products, and services.
Segments:
Keros Therapeutics Inc. is strategically organized into two primary segments:
1. Oncology:
This segment is concentrated on developing innovative treatments for various cancers. Keros recognizes the complexity of cancer biology and aims to target specific molecular pathways and interactions that promote tumor growth and resistance to existing therapies. The ongoing research in this area aims to enhance patient outcomes in a landscape characterized by diverse and challenging malignancies.
2. Rare Diseases:
The focus on rare genetic disorders underscores Keros’s commitment to addressing diseases that often receive less attention in traditional drug development pipelines. This segment is primarily aimed at discovering and developing therapies that can significantly improve the quality of life for patients dealing with these debilitating conditions. The company seeks to leverage its expertise in protein modulation to uncover new treatment avenues for these rare disease states.
Products:
Keros Therapeutics Inc. has developed a range of promising product candidates that represent the forefront of precision medicine. The pipeline of therapeutics is bifurcated between their focus on oncology and rare diseases:
- KER-050: This is Keross lead product candidate, a small molecule inhibitor targeting the Transforming Growth Factor Beta (TGF-β) signaling pathway. KER-050 is currently under investigation for its potential to treat myelodysplastic syndromes (MDS) and solid tumors, aiming to alter the diseases course by modulating key cellular pathways.
- KER-047: A small molecule designed to inhibit the interaction between RAS and 14-3-3 proteins, this candidate is being developed for both solid tumors and hematological malignancies. By interfering with this critical PPI, KER-047 aims to selectively impact cancer cell survival and proliferation.
- KER-012: This selective inhibitor targets Fibroblast Growth Factor Receptor 3 (FGFR3), with particular focus on bladder cancer driven by activating mutations in FGFR3. This targeted approach seeks to harness precision medicine principles to improve outcomes in affected patients.
- KER-073: This small molecule inhibitor disrupts the Histone H3K27 demethylase complex, a key player in the epigenetic regulation of gene expression. KER-073 is aimed at treating pediatric brain tumors and specific oncology indications, reflecting the company’s dedication to combatting challenging and often underrepresented malignancies.
Services:
In addition to its product development efforts, Keros Therapeutics Inc. provides a suite of services that support both internal research and external collaborations. These services include:
- Drug Discovery Services: Keros offers comprehensive drug discovery services, including hit-to-lead optimization, where potential drug candidates are refined into viable therapeutic agents. They also provide target validation services to confirm the therapeutic relevance of various biological targets before advancing to pre-clinical development.
- Computational Chemistry Services: The company leverages advanced computational techniques, including molecular modeling and virtual screening, to design and optimize bioactive compounds. These services help in understanding the molecular interactions at play and aid in making informed decisions during the drug development process.
- Contract Research Services: Keros Therapeutics Inc. extends its expertise in PPI drug discovery through contract research services. These services include screening, validation, and strategic input tailored to the clients specific research goals, ensuring that the partners can benefit from Keross specialized knowledge in protein interactions.
Conclusion:
Keros Therapeutics Inc. stands at the convergence of innovation and compassion in the biopharmaceutical landscape, focusing on critical areas that have historically been underserved. With a well-defined strategy that combines oncology and rare diseases, complemented by a robust pipeline of products and extensive support services, Keros is poised to make a substantial impact on the treatment paradigms for patients facing severe health challenges. Their commitment to modulating protein interactions and targeting specific disease pathways positions them to deliver meaningful advancements in therapy and improve patient outcomes in the near future.
Segments:
Keros Therapeutics Inc. is strategically organized into two primary segments:
1. Oncology:
This segment is concentrated on developing innovative treatments for various cancers. Keros recognizes the complexity of cancer biology and aims to target specific molecular pathways and interactions that promote tumor growth and resistance to existing therapies. The ongoing research in this area aims to enhance patient outcomes in a landscape characterized by diverse and challenging malignancies.
2. Rare Diseases:
The focus on rare genetic disorders underscores Keros’s commitment to addressing diseases that often receive less attention in traditional drug development pipelines. This segment is primarily aimed at discovering and developing therapies that can significantly improve the quality of life for patients dealing with these debilitating conditions. The company seeks to leverage its expertise in protein modulation to uncover new treatment avenues for these rare disease states.
Products:
Keros Therapeutics Inc. has developed a range of promising product candidates that represent the forefront of precision medicine. The pipeline of therapeutics is bifurcated between their focus on oncology and rare diseases:
- KER-050: This is Keross lead product candidate, a small molecule inhibitor targeting the Transforming Growth Factor Beta (TGF-β) signaling pathway. KER-050 is currently under investigation for its potential to treat myelodysplastic syndromes (MDS) and solid tumors, aiming to alter the diseases course by modulating key cellular pathways.
- KER-047: A small molecule designed to inhibit the interaction between RAS and 14-3-3 proteins, this candidate is being developed for both solid tumors and hematological malignancies. By interfering with this critical PPI, KER-047 aims to selectively impact cancer cell survival and proliferation.
- KER-012: This selective inhibitor targets Fibroblast Growth Factor Receptor 3 (FGFR3), with particular focus on bladder cancer driven by activating mutations in FGFR3. This targeted approach seeks to harness precision medicine principles to improve outcomes in affected patients.
- KER-073: This small molecule inhibitor disrupts the Histone H3K27 demethylase complex, a key player in the epigenetic regulation of gene expression. KER-073 is aimed at treating pediatric brain tumors and specific oncology indications, reflecting the company’s dedication to combatting challenging and often underrepresented malignancies.
Services:
In addition to its product development efforts, Keros Therapeutics Inc. provides a suite of services that support both internal research and external collaborations. These services include:
- Drug Discovery Services: Keros offers comprehensive drug discovery services, including hit-to-lead optimization, where potential drug candidates are refined into viable therapeutic agents. They also provide target validation services to confirm the therapeutic relevance of various biological targets before advancing to pre-clinical development.
- Computational Chemistry Services: The company leverages advanced computational techniques, including molecular modeling and virtual screening, to design and optimize bioactive compounds. These services help in understanding the molecular interactions at play and aid in making informed decisions during the drug development process.
- Contract Research Services: Keros Therapeutics Inc. extends its expertise in PPI drug discovery through contract research services. These services include screening, validation, and strategic input tailored to the clients specific research goals, ensuring that the partners can benefit from Keross specialized knowledge in protein interactions.
Conclusion:
Keros Therapeutics Inc. stands at the convergence of innovation and compassion in the biopharmaceutical landscape, focusing on critical areas that have historically been underserved. With a well-defined strategy that combines oncology and rare diseases, complemented by a robust pipeline of products and extensive support services, Keros is poised to make a substantial impact on the treatment paradigms for patients facing severe health challenges. Their commitment to modulating protein interactions and targeting specific disease pathways positions them to deliver meaningful advancements in therapy and improve patient outcomes in the near future.